Inclusion Criteria • Adults 30-65 years old with elevated average blood glucose levels (100-125 mg/dL), confirmed at screening (HbA1c 5.7-6.4%)
• BMI 18.5-29.9 kg/m² (normal to overweight)
• Generally healthy individuals with no metabolic or endocrine disorders besides elevated blood glucose levels, meaning no metabolic syndrome, insulin resistance diagnosis, dyslipidemia diagnosis requiring treatment, thyroid disorders, etc.
• Stable weight for the past 3 months (±5%)
• Sedentary or lightly active baseline lifestyle (Light activity ≤3 times/week (e.g., walking, yoga, casual biking)
• Willingness to maintain usual diet, activity, and sleep patterns for 16 weeks
• Able and willing to wear a CGM for the final 10-14 days
• Willing to complete 3-day dietary recalls, sleep and activity logs
• Not taking or willing to stop taking supplements containing chromium, vitamin A, vitamin B6, iodine, and niacin
• Able and willing to provide informed consent and complete all study visits 6 Exclusion Criteria
• Any diagnosed metabolic/endocrine disorder, other than elevated blood glucose levels, such as metabolic syndrome, insulin resistance diagnosis, clinically significant dyslipidemia, thyroid dysfunction or use of thyroid medication, or obesity-related endocrine dysfunction
• Medications and supplements use of glucose-lowering medications within the past 3 months, including use of weight-loss drugs or metabolic agents, such asGLP-1 RAs (Ozempic, Wegovy, Rybelsus, Trulicity, Victoza, Saxenda) or GIP/GLP-1 RAas (Mounjaro, Zepbound)
• Use of supplements within the last 30 days containing chromium, vitamin A, vitamin B6, niacin, iodine
• Unwilling to discontinue prohibited supplements
• Health Conditions \& safety such as elevated ALT/AST more than 2× the upper limit or known chronic liver disease or diagnosed renal impairment (eGFR \<45 mL/min/1.73 m²), uncontrolled hypertension (\>160/100 mmHg)
• Pregnant, breastfeeding, or planning pregnancy
• Allergy or sensitivity to study ingredients or CGM adhesives
• Lifestyle and compliance (\>30 minutes/day of intense physical activity (active adults or athletes))
• Participation in another investigational trial in the past 30 days
• Any condition that may interfere with participation or data quality (per investigator guidance)
